ATE375344T1 - Azolotriazine und pyrimidine - Google Patents
Azolotriazine und pyrimidineInfo
- Publication number
- ATE375344T1 ATE375344T1 AT97936222T AT97936222T ATE375344T1 AT E375344 T1 ATE375344 T1 AT E375344T1 AT 97936222 T AT97936222 T AT 97936222T AT 97936222 T AT97936222 T AT 97936222T AT E375344 T1 ATE375344 T1 AT E375344T1
- Authority
- AT
- Austria
- Prior art keywords
- azolotriazines
- pyrimidines
- Prior art date
Links
- 150000003230 pyrimidines Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68604796A | 1996-07-24 | 1996-07-24 | |
| US2329096P | 1996-07-24 | 1996-07-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE375344T1 true ATE375344T1 (de) | 2007-10-15 |
Family
ID=26696934
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97936222T ATE375344T1 (de) | 1996-07-24 | 1997-07-23 | Azolotriazine und pyrimidine |
Country Status (17)
| Country | Link |
|---|---|
| EP (2) | EP1908764A1 (de) |
| KR (1) | KR100548853B1 (de) |
| AR (1) | AR007994A1 (de) |
| AT (1) | ATE375344T1 (de) |
| AU (1) | AU747708B2 (de) |
| CZ (1) | CZ2005613A3 (de) |
| DE (1) | DE69738197T2 (de) |
| DK (1) | DK0915880T3 (de) |
| EA (1) | EA006626B1 (de) |
| ES (1) | ES2294800T3 (de) |
| HK (1) | HK1052693A1 (de) |
| HU (2) | HU229024B1 (de) |
| LV (1) | LV12292B (de) |
| PT (1) | PT915880E (de) |
| RO (1) | RO121272B1 (de) |
| TW (2) | TWI238164B (de) |
| WO (1) | WO1998003510A1 (de) |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7094782B1 (en) | 1996-07-24 | 2006-08-22 | Bristol-Myers Squibb Company | Azolo triazines and pyrimidines |
| AU6279598A (en) * | 1997-02-18 | 1998-09-08 | Neurocrine Biosciences, Inc. | Biazacyclic CRF antagonists |
| PL200939B1 (pl) * | 1998-01-28 | 2009-02-27 | Bristol Myers Squibb Pharma Co | Związki [1,5-a]-pirazolo-1,3,5-triazynowe, środek farmaceutyczny i zastosowanie tych związków |
| WO1999045007A1 (en) * | 1998-03-06 | 1999-09-10 | Janssen Pharmaceutica N.V. | Crf antagonistic pyrazolo[4,3-b]pyridines |
| US6509338B1 (en) | 1998-06-22 | 2003-01-21 | Bristol-Myers Squibb Company | Pyrazolo[1,5-A]triazine corticotropin releasing factor antagonists |
| DK1129096T3 (da) | 1998-11-12 | 2003-09-15 | Neurocrine Biosciences Inc | CRF-receptorantagonister og fremgangsmåder, der er relateret dertil |
| ES2180338T3 (es) | 1998-11-12 | 2003-02-01 | Neurocrine Biosciences Inc | Antagonistas del receptor de crf y metodos relacionados. |
| AU4331500A (en) | 1999-04-06 | 2000-10-23 | Du Pont Pharmaceuticals Company | Pyrazolotriazines as crf antagonists |
| AU4203500A (en) | 1999-04-06 | 2000-10-23 | Du Pont Pharmaceuticals Company | Pyrazolopyrimidines as crf antagonists |
| US6432989B1 (en) | 1999-08-27 | 2002-08-13 | Pfizer Inc | Use of CRF antagonists to treat circadian rhythm disorders |
| KR20020047198A (ko) * | 1999-09-30 | 2002-06-21 | 해피 페너 ; 해리 에이치. 페너 2세 | 특정 알킬렌 디아민-치환된피라졸로[1,5-ａ]-1,5-피리미딘 및피라졸로[1,5-ａ]-1,3,5-트리아진 |
| YU23602A (sh) * | 1999-09-30 | 2004-09-03 | Neurogen Corporation | Amino supstituisani pirazolo /1,5/a/-1,5-pirimidini i pirazolo /1,5-a/-1,3,5-triazini |
| OA12050A (en) * | 1999-09-30 | 2006-05-02 | Neurogen Corp | Certain alkylene diamine-substituted heterocycles. |
| KR20030016222A (ko) * | 2000-02-14 | 2003-02-26 | 니뽄 다바코 산교 가부시키가이샤 | 수술후 스트레스 예방ㆍ치료제 |
| US6589952B2 (en) | 2000-07-14 | 2003-07-08 | Bristol-Myers Squibb Pharma Company | Imidazo[1,2-a]pyrazines for the treatment of neurological disorders |
| EP1305637A2 (de) * | 2000-08-02 | 2003-05-02 | Malope Company Limited | Diagnose und behandlung nichtulzerativer dyspepsie auf basis von abnormalitäten der hypothalamus-hypophise-adrenal-achse |
| JP4549630B2 (ja) | 2001-03-13 | 2010-09-22 | ブリストル−マイヤーズ スクイブ ファーマ カンパニー | コルチコトロピン放出因子受容体リガンドとしての、４−（２−ブチルアミノ）−２，７−ジメチル−８−（２−メチル−６−メトキシピリド−３−イル）ピラゾロ−［１，５−ａ］−１，３，５−トリアジン、その鏡像異性体および薬学的に許容できる塩類 |
| US7205306B2 (en) | 2001-05-14 | 2007-04-17 | Bristol-Myers Squibb Pharma Company | Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor ligands |
| AU2002354575A1 (en) | 2001-07-12 | 2003-01-29 | Bristol-Myers Squibb Pharma Company | Tetrahydropurinones as corticotropin releasing factor |
| WO2003006015A1 (en) | 2001-07-13 | 2003-01-23 | Bristol-Myers Squibb Pharma Company | Substituted thiazoles and oxazoles as corticotropin releasing hormone ligands |
| AU2002340405A1 (en) | 2001-11-20 | 2003-06-10 | Bristol-Myers Squibb Pharma Company | 3,7-dihydro-purine-2,6-dione derivatives as crf receptor ligands |
| EP1485385B1 (de) | 2002-03-07 | 2005-08-17 | SmithKline Beecham Corporation | Pyrazolopyrimidin- und pyrazolotriazinderivate und diese enthaltende pharmazeutische zubereitungen |
| DK1501809T3 (da) * | 2002-04-26 | 2008-05-13 | Lilly Co Eli | Trizolderivater som tachykininreceptorantagonister |
| FR2842809A1 (fr) * | 2002-07-26 | 2004-01-30 | Greenpharma Sas | NOUVELLES PYRAZOLO[1,5-a]-1,3,5-TRIAZINES SUBSTITUEES ET LEURS ANALOGUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION |
| FR2850653A1 (fr) * | 2003-02-04 | 2004-08-06 | Univ Pasteur | Derives de pyrazolotriazine, procede de preparation et utilisations |
| US7329658B2 (en) | 2003-02-06 | 2008-02-12 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
| US7112585B2 (en) | 2003-04-18 | 2006-09-26 | Bristol-Myers Squibb Company | Pyrimidine derivatives as corticotropin releasing factor inhibitors |
| US7030145B2 (en) | 2003-04-18 | 2006-04-18 | Bristol-Myers Squibb Company | Pyridinyl derivatives for the treatment of depression |
| US7153961B2 (en) | 2003-11-25 | 2006-12-26 | Bristol-Myers Squibb Pharma Co. | Salt and crystalline form thereof of a corticotropin releasing factor receptor antagonist |
| US7208596B2 (en) | 2003-11-25 | 2007-04-24 | Bristol-Myers Squibb Pharma Company | Processes for the preparation of pyrazolo[1,5-a]-1,3,5-triazines and intermediates thereof |
| NZ547990A (en) | 2003-12-22 | 2010-04-30 | Smithkline Beecham Cork Ltd | CRF receptor antagonists and methods relating thereto |
| GB0519957D0 (en) | 2005-09-30 | 2005-11-09 | Sb Pharmco Inc | Chemical compound |
| JP2009502734A (ja) * | 2005-07-29 | 2009-01-29 | アステラス製薬株式会社 | Ｌｃｋ阻害剤としての縮合複素環 |
| UA96458C2 (ru) * | 2006-09-20 | 2011-11-10 | Эли Лилли Энд Компани | Тиазолпиразолопиримидиновые соединения как антагонисты рецептора crf1 |
| CA2662000C (en) | 2006-09-20 | 2013-01-08 | Eli Lilly And Company | Thiophene pyrazolopyrimidine compounds |
| JP5442449B2 (ja) | 2006-12-22 | 2014-03-12 | アステックス、セラピューティックス、リミテッド | 新規化合物 |
| EP2114941B1 (de) | 2006-12-22 | 2015-03-25 | Astex Therapeutics Limited | Bicyclische heterocyclische verbindungen als fgfr-inhibitoren |
| EP2167094A2 (de) * | 2007-06-13 | 2010-03-31 | Research Development Foundation | Verfahren zur behandlung und prävention von tauopathien und amyloid-beta-amyloidose durch modulierung der crf-rezeptor-signalgebung |
| GB0720038D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New compounds |
| GB0720041D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New Compounds |
| GB0810902D0 (en) | 2008-06-13 | 2008-07-23 | Astex Therapeutics Ltd | New compounds |
| US8591943B2 (en) | 2009-04-09 | 2013-11-26 | Merck Sharp & Dohme Corp. | Pyrazolo[1,5-a]pyrimidine derivatives as mTOR inhibitors |
| GB0906470D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
| GB0906472D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
| EP2264035A1 (de) * | 2009-06-04 | 2010-12-22 | Merz Pharma GmbH & Co. KGaA | Glycin-B-Antagonisten |
| JP2014517079A (ja) | 2011-06-22 | 2014-07-17 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ阻害剤として有用な化合物 |
| PT2760453T (pt) | 2011-09-30 | 2016-08-02 | Ipsen Pharma Sas | Inibidores macrocíclicos da cinase lrrk2 |
| GB201210686D0 (en) | 2012-06-15 | 2012-08-01 | Holsboermaschmeyer Neurochemie Gmbh | V1B receptor antagonist for use in the treatment of patients having an elevated AVP level and/or an elevated copeptin level |
| WO2014078568A1 (en) | 2012-11-14 | 2014-05-22 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| US8871754B2 (en) | 2012-11-19 | 2014-10-28 | Irm Llc | Compounds and compositions for the treatment of parasitic diseases |
| SI2925757T1 (en) | 2012-11-19 | 2018-01-31 | Novartis Ag | Compounds and compositions for the treatment of parasitic diseases |
| SMT202000713T1 (it) | 2012-12-07 | 2021-03-15 | Vertex Pharma | Pirazolo [1,5-a] pirimidine utili come inibitori dell'atr chinasi per il trattamento di malattie del cancro |
| EP2968220B1 (de) | 2013-03-15 | 2021-05-05 | Agenebio, Inc. | Verfahren und zusammensetzungen zur verbesserung von kognitiven funktionen |
| WO2014144663A1 (en) | 2013-03-15 | 2014-09-18 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| GB201310782D0 (en) | 2013-06-17 | 2013-07-31 | Max Planck Innovation Gmbh | Method for predicting a treatment response to a CRHR1 antagonist and/or V1B antagonist in a patient with depressive and/or anxiety symptoms |
| HUE046727T2 (hu) | 2013-12-06 | 2020-03-30 | Vertex Pharma | Az ATR-kináz inhibitoraként használható vegyület, 2-amino-6-fluoro-N-[5-fluoro-piridin-3-IL]-pirazolo-[1,5-A]-pirimidin-3-karboxamid, ennek elõállítása, különbözõ szilárd formái és ezek radioaktív nyomjelzett származékai |
| CN107074863B (zh) | 2014-06-05 | 2019-12-03 | 沃泰克斯药物股份有限公司 | Atr激酶抑制剂的制备方法及其不同的固体形式 |
| PL3157566T3 (pl) | 2014-06-17 | 2019-10-31 | Vertex Pharma | Metoda leczenia nowotworu przy użyciu kombinacji inhibitorów chk1 i atr |
| KR20170048599A (ko) | 2014-09-17 | 2017-05-08 | 온코디자인 에스.에이. | 거대 고리 ｌｒｒｋ2 키아나제 저해제 |
| WO2016071216A1 (en) | 2014-11-03 | 2016-05-12 | Bayer Pharma Aktiengesellschaft | Piperidinylpyrazolopyrimidinones and their use |
| NZ738682A (en) | 2015-05-22 | 2022-01-28 | Agenebio Inc | Extended release pharmaceutical compositions of levetiracetam |
| KR102678021B1 (ko) | 2015-09-30 | 2024-06-26 | 버텍스 파마슈티칼스 인코포레이티드 | Dna 손상제와 병용되는, atr 저해제를 포함하는 암 치료용 약제학적 조성물 |
| FI3612030T3 (fi) * | 2017-04-21 | 2026-03-20 | Pahr Therapeutics Inc | Ahr:n indoliestäjiä ja niiden käyttötapoja |
| KR20250022913A (ko) | 2017-08-14 | 2025-02-17 | 스프루스 바이오사이언시스 인코포레이티드 | 코티코트로핀 방출 인자 수용체 길항제 |
| JP2021512959A (ja) * | 2018-02-06 | 2021-05-20 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司Ｊｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．， Ｌｔｄ． | ピラゾロ［１，５−ａ］［１，３，５］トリアジン−２−アミン誘導体、その製造法、およびその医薬用途 |
| CN112423747A (zh) | 2018-04-27 | 2021-02-26 | 云杉生物科学公司 | 用于治疗睾丸肾上腺残余瘤和卵巢肾上腺残余瘤的方法 |
| IL282254B2 (en) | 2018-10-30 | 2025-08-01 | Kronos Bio Inc | Compounds, compositions, and methods for modulating cdk9 activity |
| MX2023001688A (es) | 2020-08-12 | 2023-02-22 | Spruce Biosciences Inc | Metodos y composiciones para tratar el sindrome de ovario poliquistico. |
| US11708372B2 (en) | 2021-11-19 | 2023-07-25 | Spruce Biosciences, Inc. | Crystalline composition of tildacerfont and methods of use and preparation thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE786611A (fr) * | 1971-08-16 | 1973-01-22 | Int Chem & Nuclear Corp | Nouveaux inhibiteurs de xanthine-oxydase et leur procede de preparatio |
| US3910907A (en) * | 1973-07-09 | 1975-10-07 | Icn Pharmaceuticals | Pyrazolo(1,5-a)-1,3,5-triazines |
| US3995039A (en) * | 1975-05-27 | 1976-11-30 | Merck & Co., Inc. | Pyrazolo [1,5-a] [1,3,5] triazines |
| JPS6157587A (ja) * | 1984-08-29 | 1986-03-24 | Shionogi & Co Ltd | 縮合複素環誘導体および抗潰瘍剤 |
| US4824834A (en) * | 1986-10-31 | 1989-04-25 | Otsuka Pharmaceutical Company, Limited | Pyrazolotriazine compounds |
| DE3722072A1 (de) * | 1987-07-01 | 1989-01-12 | Schering Ag | 6,7-dihydro-pyrazolo(1,5-a)(1,3,5) triazin-2-sulfonsaeureamide, verfahren zu ihrer herstellung und ihre verwendung als mittel mit herbizider und pflanzenwuchsregulierender wirkung |
| JP2585462B2 (ja) * | 1989-10-25 | 1997-02-26 | 株式会社大塚製薬工場 | ピラゾロ［１，５―ａ］ピリミジン誘導体 |
| US5420128A (en) * | 1990-10-09 | 1995-05-30 | Otsuka Pharmaceutical Co., Ltd. | Pyrimidine derivatives, method of manufacturing the same, and androgen inhibitor |
| US5484760A (en) * | 1990-12-31 | 1996-01-16 | Monsanto Company | Herbicide antidotes as safeners for reducing phytotoxicity resulting from synergistic interaction between herbicides and other pesticides |
| WO1992018504A1 (en) * | 1991-04-22 | 1992-10-29 | Otsuka Pharmaceutical Factory, Inc. | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVE AND ANTI-INFLAMMATORY CONTAINING THE SAME |
| US5356897A (en) * | 1991-09-09 | 1994-10-18 | Fujisawa Pharmaceutical Co., Ltd. | 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines |
| ES2128544T3 (es) * | 1992-12-17 | 1999-05-16 | Pfizer | Pirrolopirimidinas como antagonistas del crf. |
| KR100315837B1 (ko) * | 1994-06-21 | 2002-02-28 | 고리 히데아끼 | 피라졸로[1,5-a]피리미딘유도체 |
| JPH10506126A (ja) * | 1995-05-12 | 1998-06-16 | ニューロゲン コーポレイション | 新規なデアザプリン誘導体；ｃｒｆ１特異性リガンドの新規なクラス |
| WO1997029109A1 (en) * | 1996-02-07 | 1997-08-14 | Janssen Pharmaceutica N.V. | Pyrazolopyrimidines as crf receptor antagonists |
-
1997
- 1997-07-23 HU HU0500549A patent/HU229024B1/hu unknown
- 1997-07-23 DE DE69738197T patent/DE69738197T2/de not_active Expired - Lifetime
- 1997-07-23 EP EP07015514A patent/EP1908764A1/de not_active Withdrawn
- 1997-07-23 EA EA200301042A patent/EA006626B1/ru not_active IP Right Cessation
- 1997-07-23 AT AT97936222T patent/ATE375344T1/de active
- 1997-07-23 DK DK97936222T patent/DK0915880T3/da active
- 1997-07-23 PT PT97936222T patent/PT915880E/pt unknown
- 1997-07-23 WO PCT/US1997/013072 patent/WO1998003510A1/en not_active Ceased
- 1997-07-23 EP EP97936222A patent/EP0915880B1/de not_active Expired - Lifetime
- 1997-07-23 HU HU0102187A patent/HU228962B1/hu unknown
- 1997-07-23 CZ CZ2005-613A patent/CZ2005613A3/cs unknown
- 1997-07-23 RO RO99-00078A patent/RO121272B1/ro unknown
- 1997-07-23 AU AU38942/97A patent/AU747708B2/en not_active Expired
- 1997-07-23 ES ES97936222T patent/ES2294800T3/es not_active Expired - Lifetime
- 1997-07-23 KR KR1019997000568A patent/KR100548853B1/ko not_active Expired - Fee Related
- 1997-07-24 AR ARP970103368A patent/AR007994A1/es unknown
- 1997-07-25 TW TW092105694A patent/TWI238164B/zh not_active IP Right Cessation
- 1997-07-25 TW TW086110640A patent/TW542827B/zh not_active IP Right Cessation
-
1999
- 1999-01-20 LV LVP-99-13A patent/LV12292B/en unknown
-
2003
- 2003-07-02 HK HK03104703.7A patent/HK1052693A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW542827B (en) | 2003-07-21 |
| RO121272B1 (ro) | 2007-02-28 |
| HU0500549D0 (en) | 2005-08-29 |
| KR100548853B1 (ko) | 2006-02-02 |
| AU3894297A (en) | 1998-02-10 |
| DK0915880T3 (da) | 2008-02-11 |
| ES2294800T3 (es) | 2008-04-01 |
| EP1908764A1 (de) | 2008-04-09 |
| DE69738197D1 (de) | 2007-11-22 |
| KR20000068010A (ko) | 2000-11-25 |
| WO1998003510A1 (en) | 1998-01-29 |
| EP0915880A1 (de) | 1999-05-19 |
| PT915880E (pt) | 2007-12-31 |
| HK1052693A1 (zh) | 2003-09-26 |
| TWI238164B (en) | 2005-08-21 |
| EA006626B1 (ru) | 2006-02-24 |
| HUP0102187A3 (en) | 2002-12-28 |
| LV12292A (lv) | 1999-06-20 |
| CZ2005613A3 (cs) | 2017-01-25 |
| TW200304916A (en) | 2003-10-16 |
| AU747708B2 (en) | 2002-05-23 |
| LV12292B (en) | 1999-11-20 |
| EA200301042A1 (ru) | 2004-02-26 |
| HU229024B1 (en) | 2013-07-29 |
| HUP0102187A2 (hu) | 2001-11-28 |
| EP0915880B1 (de) | 2007-10-10 |
| DE69738197T2 (de) | 2008-07-17 |
| AR007994A1 (es) | 1999-11-24 |
| HU228962B1 (en) | 2013-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69738197D1 (de) | Azolotriazine und pyrimidine | |
| PL335258A1 (en) | Arylamine-condensed pyridines and pyrimidines | |
| DE69828963D1 (de) | Wirstoffabgabe und gentherapiesystem | |
| DK1115721T3 (da) | Pyrimidonderivater | |
| FI972087A0 (fi) | Dihydropyrimidiineja ja niiden käyttöjä | |
| ATE318746T1 (de) | Lasttragende und steuerbare einheit | |
| DK0977737T3 (da) | CRF-antagonistisk quino- og quinazoline | |
| ATE223401T1 (de) | Dihydropyrimidine | |
| DE69941934D1 (de) | Hiv-replikationshemmende Pyrimidine | |
| BR9509768A (pt) | Novas pirimidinas de benzila | |
| FI970150L (fi) | Substituoituja pyrimidiiniyhdisteitä ja niiden käyttö | |
| DE69831750D1 (de) | Biozide und biozide tücher | |
| ZA971896B (en) | Aryloxy-and arythio-fused pyridines and pyrimidines and derivatives | |
| DE69619125D1 (de) | Amino substituierte pyrimidinen und triazinen | |
| ZA972553B (en) | Aryloxy-and arylthio- substituted pyrimidines and triazines and derivatives thereof | |
| NO990264D0 (no) | Azolotriaziner og -pyrimidiner | |
| FI972795L (fi) | Pyrimidiinijohdannaisia | |
| IL130180A0 (en) | Substituted pyrimidine compounds and their use | |
| EP1073458A4 (de) | Chlamydia proteine und ihre verwendung | |
| DE69716181D1 (de) | Herbizide 6-Thienyl und 4-Thienyl Pyrimidine | |
| EP0998578A4 (de) | Sel-10 und dessen verwendungen | |
| DE69628756D1 (de) | Kombinierte longitudinale und transversale Spurnachführung | |
| ID16730A (id) | Dihidro pirimidina dan penggunaannya | |
| ZA9811565B (en) | Novel pyridine and pyrimidine derivatives | |
| DE59812220D1 (de) | Halte- und trageband |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0915880 Country of ref document: EP |